|
1
|
Choi KT: Botanical characteristics,
pharmacological effects and medicinal components of Korean Panax
ginseng C A Meyer. Acta Pharmacol Sin. 29:1109–1118. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shibata S: Chemistry and cancer preventing
activities of ginseng saponins and some related triterpenoid
compounds. J Korean Med Sci. 16(Suppl): S28–S37. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kitagawa I, Taniyama T, Shibuya H, Noda T
and Yoshikawa M: Chemical studies on crude drug processing. V. On
the constituents of ginseng radix rubra (2): Comparison of the
constituents of white ginseng and red ginseng prepared from the
same Panax ginseng root. Yakugaku Zasshi. 107:495–505.
1987.(In Japanese).
|
|
4
|
Kitagawa I, Yoshikawa M, Yoshihara M,
Hayashi T and Taniyama T: Chemical studies of crude drugs (1).
Constituents of Ginseng radix rubra. Yakugaku Zasshi. 103:612–622.
1983.(In Japanese).
|
|
5
|
Shin HR, Kim JY, Yun TK, Morgan G and
Vainio H: The cancer-preventive potential of Panax ginseng:
a review of human and experimental evidence. Cancer Causes Control.
11:565–576. 2000. View Article : Google Scholar
|
|
6
|
Yun TK, Lee YS, Lee YH, Kim SI and Yun HY:
Anticarcinogenic effect of Panax ginseng C.A. Meyer and
identification of active compounds. J Korean Med Sci. 16(Suppl):
S6–S18. 2001.
|
|
7
|
Nag SA, Qin JJ, Wang W, Wang MH, Wang H
and Zhang R: Ginsenosides as anticancer agents: In vitro and in
vivo activities, structure-activity relationships, and molecular
mechanisms of action. Front Pharmacol. 3:252012.PubMed/NCBI
|
|
8
|
Qi LW, Wang CZ and Yuan CS: Ginsenosides
from American ginseng: chemical and pharmacological diversity.
Phytochemistry. 72:689–699. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hofseth LJ and Wargovich MJ: Inflammation,
cancer, and targets of ginseng. J Nutr. 137(Suppl 1): 183S–185S.
2007.PubMed/NCBI
|
|
10
|
Kim YS and Jin SH: Ginsenoside Rh2 induces
apoptosis via activation of caspase-1 and -3 and up-regulation of
Bax in human neuroblastoma. Arch Pharm Res. 27:834–839. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Keum YS, Han SS, Chun KS, et al:
Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced
cyclooxygenase-2 expression, NF-kappaB activation and tumor
promotion. Mutat Res. 523–524:75–85. 2003.PubMed/NCBI
|
|
12
|
Kumar A, Kumar M, Panwar M, et al:
Evaluation of chemopreventive action of Ginsenoside Rp1.
Biofactors. 26:29–43. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bae JS, Park HS, Park JW, Li SH and Chun
YS: Red ginseng and 20(S)-Rg3 control testosterone-induced prostate
hyperplasia by deregulating androgen receptor signaling. J Nat Med.
66:476–485. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He BC, Gao JL, Luo X, et al: Ginsenoside
Rg3 inhibits colorectal tumor growth through the down-regulation of
Wnt/β-catenin signaling. Int J Oncol. 38:437–445. 2011.PubMed/NCBI
|
|
15
|
Liu TG, Huang Y, Cui DD, et al: Inhibitory
effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis
and growth of lung cancer in mice. BMC Cancer. 9:2502009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Musende AG, Eberding A, Wood C, et al:
Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for
prostate cancer in vivo: formulation, pharmacokinetics,
biodistribution and efficacy. Cancer Chemother Pharmacol.
64:1085–1095. 2009. View Article : Google Scholar
|
|
17
|
Hu C, Song G, Zhang B, et al: Intestinal
metabolite compound K of panaxoside inhibits the growth of gastric
carcinoma by augmenting apoptosis via Bid-mediated mitochondrial
pathway. J Cell Mol Med. 16:96–106. 2012. View Article : Google Scholar
|
|
18
|
Wang W, Rayburn ER, Hang J, Zhao Y, Wang H
and Zhang R: Anti-lung cancer effects of novel ginsenoside
25-OCH(3)-PPD. Lung Cancer. 65:306–311. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang W, Rayburn ER, Zhao Y, Wang H and
Zhang R: Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as
experimental therapy for pancreatic cancer: anticancer activity and
mechanisms of action. Cancer Lett. 278:241–248. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang W, Zhang X, Qin JJ, et al: Natural
product ginsenoside 25-OCH3-PPD inhibits breast cancer
growth and metastasis through down-regulating MDM2. PLoS One.
7:e415862012.PubMed/NCBI
|
|
21
|
Wang W, Rayburn ER, Hao M, et al:
Experimental therapy of prostate cancer with novel natural product
anti-cancer ginsenosides. Prostate. 68:809–819. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lü JM, Weakley SM, Yang Z, Hu M, Yao Q and
Chen C: Ginsenoside rb1 directly scavenges hydroxyl radical and
hypochlorous acid. Curr Pharm Des. 18:6339–6347. 2012.PubMed/NCBI
|
|
23
|
Park HM, Kim SJ, Mun AR, et al: Korean red
ginseng and its primary ginsenosides inhibit ethanol-induced
oxidative injury by suppression of the MAPK pathway in TIB-73
cells. J Ethnopharmacol. 141:1071–1076. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim YH, Park KH and Rho HM:
Transcriptional activation of the Cu,Zn-superoxide dismutase gene
through the AP2 site by ginsenoside Rb2 extracted from a medicinal
plant, Panax ginseng. J Biol Chem. 271:24539–24543. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chang MS, Lee SG and Rho HM:
Transcriptional activation of Cu/Zn superoxide dismutase and
catalase genes by panaxadiol ginsenosides extracted from Panax
ginseng. Phytother Res. 13:641–644. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim ND, Pokharel YR and Kang KW:
Ginsenoside Rd enhances glutathione levels in H4IIE cells via
NF-kappaB-dependent gamma-glutamylcysteine ligase induction.
Pharmazie. 62:933–936. 2007.PubMed/NCBI
|
|
27
|
Lee SH, Seo GS, Ko G, Kim JB and Sohn DH:
Anti-inflammatory activity of 20(S)-protopanaxadiol: enhanced heme
oxygenase 1 expression in RAW 264.7 cells. Planta Med.
71:1167–1170. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Saw CL, Yang AY, Cheng DC, et al:
Pharmacodynamics of ginsenosides: antioxidant activities,
activation of Nrf2, and potential synergistic effects of
combinations. Chem Res Toxicol. 25:1574–1580. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shin YM, Jung HJ, Choi WY and Lim CJ:
Antioxidative, anti-inflammatory, and matrix metalloproteinase
inhibitory activities of 20(S)-ginsenoside Rg3 in cultured
mammalian cell lines. Mol Biol Rep. 40:269–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim TW, Joh EH, Kim B and Kim DH:
Ginsenoside Rg5 ameliorates lung inflammation in mice by inhibiting
the binding of LPS to toll-like receptor-4 on macrophages. Int
Immunopharmacol. 12:110–116. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Joh EH, Lee IA, Jung IH and Kim DH:
Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1
activation - the key step of inflammation. Biochem Pharmacol.
82:278–286. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang XL, Guo TK, Wang YH, et al:
Ginsenoside Rd attenuates the inflammatory response via modulating
p38 and JNK signaling pathways in rats with TNBS-induced relapsing
colitis. Int Immunopharmacol. 12:408–414. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Park EK, Shin YW, Lee HU, et al:
Inhibitory effect of ginsenoside Rb1 and compound K on NO and
prostaglandin E2 biosyntheses of RAW264.7 cells induced by
lipopolysaccharide. Biol Pharm Bull. 28:652–656. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Oh GS, Pae HO, Choi BM, et al:
20(S)-Protopanaxatriol, one of ginsenoside metabolites, inhibits
inducible nitric oxide synthase and cyclooxygenase-2 expressions
through inactivation of nuclear factor-kappaB in RAW 264.7
macrophages stimulated with lipopolysaccharide. Cancer Lett.
205:23–29. 2004. View Article : Google Scholar
|
|
35
|
Huang J, Ding L, Shi D, et al: Transient
receptor potential vanilloid-1 participates in the inhibitory
effect of ginsenoside Rg1 on capsaicin-induced interleukin-8 and
prostaglandin E2 production in HaCaT cells. J Pharm Pharmacol.
64:252–258. 2012. View Article : Google Scholar
|
|
36
|
Huang J, Qiu L, Ding L, et al: Ginsenoside
Rb1 and paeoniflorin inhibit transient receptor potential
vanilloid-1-activated IL-8 and PGE2 production in a
human keratinocyte cell line HaCaT. Int Immunopharmacol.
10:1279–1283. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu WK, Xu SX and Che CT:
Anti-proliferative effect of ginseng saponins on human prostate
cancer cell line. Life Sci. 67:1297–1306. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jiang JW, Chen XM, Chen XH and Zheng SS:
Ginsenoside Rg3 inhibit hepatocellular carcinoma growth via
intrinsic apoptotic pathway. World J Gastroenterol. 17:3605–3613.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Park HM, Kim SJ, Kim JS and Kang HS:
Reactive oxygen species mediated ginsenoside Rg3- and Rh2-induced
apoptosis in hepatoma cells through mitochondrial signaling
pathways. Food Chem Toxicol. 50:2736–2741. 2012. View Article : Google Scholar
|
|
40
|
Zhang C, Liu L, Yu Y, Chen B, Tang C and
Li X: Antitumor effects of ginsenoside Rg3 on human hepatocellular
carcinoma cells. Mol Med Rep. 5:1295–1298. 2012.PubMed/NCBI
|
|
41
|
Yuan HD, Quan HY, Zhang Y, Kim SH and
Chung SH: 20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon
cancer cells is associated with AMPK signaling pathway. Mol Med
Rep. 3:825–831. 2010.PubMed/NCBI
|
|
42
|
Lee JY, Jung KH, Morgan MJ, et al:
Sensitization of TRAIL-induced cell death by 20S-Ginsenoside Rg3
via CHOP-mediated DR5 upregulation in human hepatocellular
carcinoma cells. Mol Cancer Ther. 12:274–285. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kim BJ, Nah SY, Jeon JH, So I and Kim SJ:
Transient receptor potential melastatin 7 channels are involved in
ginsenoside Rg3-induced apoptosis in gastric cancer cells. Basic
Clin Pharmacol Toxicol. 109:233–239. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chen J, Peng H, Ou-Yang X and He X:
Research on the antitumor effect of ginsenoside Rg3 in B16 melanoma
cells. Melanoma Res. 18:322–329. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li B, Zhao J, Wang CZ, et al: Ginsenoside
Rh2 induces apoptosis and paraptosis-like cell death in colorectal
cancer cells through activation of p53. Cancer Lett. 301:185–192.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Choi S, Oh JY and Kim SJ: Ginsenoside Rh2
induces Bcl-2 family proteins-mediated apoptosis in vitro and in
xenografts in vivo models. J Cell Biochem. 112:330–340. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kim HE, Oh JH, Lee SK and Oh YJ:
Ginsenoside RH-2 induces apoptotic cell death in rat C6 glioma via
a reactive oxygen- and caspase-dependent but Bcl-X(L)-independent
pathway. Life Sci. 65:PL33–PL40. 1999.PubMed/NCBI
|
|
48
|
Kim YS, Jin SH, Lee YH, Kim SI and Park
JD: Ginsenoside Rh2 induces apoptosis independently of Bcl-2,
Bcl-xL, or Bax in C6Bu-1 cells. Arch Pharm Res. 22:448–453. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Park JA, Lee KY, Oh YJ, Kim KW and Lee SK:
Activation of caspase-3 protease via a Bcl-2-insensitive pathway
during the process of ginsenoside Rh2-induced apoptosis. Cancer
Lett. 121:73–81. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Popovich DG and Kitts DD: Ginsenosides
20(S)-protopanaxadiol and Rh2 reduce cell proliferation and
increase sub-G1 cells in two cultured intestinal cell lines,
Int-407 and Caco-2. Can J Physiol Pharmacol. 82:183–190. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Oh M, Choi YH, Choi S, et al:
Anti-proliferating effects of ginsenoside Rh2 on MCF-7 human breast
cancer cells. Int J Oncol. 14:869–875. 1999.PubMed/NCBI
|
|
52
|
Cheng CC, Yang SM, Huang CY, Chen JC,
Chang WM and Hsu SL: Molecular mechanisms of ginsenoside
Rh2-mediated G1 growth arrest and apoptosis in human lung
adenocarcinoma A549 cells. Cancer Chemother Pharmacol. 55:531–540.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Oh JI, Chun KH, Joo SH, Oh YT and Lee SK:
Caspase-3-dependent protein kinase C delta activity is required for
the progression of Ginsenoside-Rh2-induced apoptosis in SK-HEP-1
cells. Cancer Lett. 230:228–238. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ham YM, Lim JH, Na HK, et al:
Ginsenoside-Rh2-induced mitochondrial depolarization and apoptosis
are associated with reactive oxygen species- and
Ca2+-mediated c-Jun NH2-terminal kinase 1 activation in
HeLa cells. J Pharmacol Exp Ther. 319:1276–1285. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Park EK, Lee EJ, Lee SH, et al: Induction
of apoptosis by the ginsenoside Rh2 by internalization of lipid
rafts and caveolae and inactivation of Akt. Br J Pharmacol.
160:1212–1223. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yi JS, Choo HJ, Cho BR, et al: Ginsenoside
Rh2 induces ligand-independent Fas activation via lipid raft
disruption. Biochem Biophys Res Commun. 385:154–159. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
An IS, An S, Kwon KJ, Kim YJ and Bae S:
Ginsenoside Rh2 mediates changes in the microRNA expression profile
of human non-small cell lung cancer A549 cells. Oncol Rep.
29:523–528. 2013.PubMed/NCBI
|
|
58
|
Wu N, Wu GC, Hu R, Li M and Feng H:
Ginsenoside Rh2 inhibits glioma cell proliferation by targeting
microRNA-128. Acta Pharmacol Sin. 32:345–353. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Park TY, Park MH, Shin WC, et al:
Anti-metastatic potential of ginsenoside Rp1, a novel ginsenoside
derivative. Biol Pharm Bull. 31:1802–1805. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kang JH, Song KH, Woo JK, et al:
Ginsenoside Rp1 from Panax ginseng exhibits anti-cancer
activity by down-regulation of the IGF-1R/Akt pathway in breast
cancer cells. Plant Foods Hum Nutr. 66:298–305. 2011.
|
|
61
|
Kumar A, Kumar M, Park TY, et al:
Molecular mechanisms of ginsenoside Rp1-mediated growth arrest and
apoptosis. Int J Mol Med. 24:381–386. 2009.PubMed/NCBI
|
|
62
|
Kim JS, Joo EJ, Chun J, et al: Induction
of apoptosis by ginsenoside Rk1 in SK-MEL-2-human melanoma. Arch
Pharm Res. 35:717–722. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kim YJ, Kwon HC, Ko H, et al: Anti-tumor
activity of the ginsenoside Rk1 in human hepatocellular carcinoma
cells through inhibition of telomerase activity and induction of
apoptosis. Biol Pharm Bull. 31:826–830. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kim SE, Lee YH, Park JH and Lee SK:
Ginsenoside-Rs3, a new diol-type ginseng saponin, selectively
elevates protein levels of p53 and p21WAF1 leading to induction of
apoptosis in SK-HEP-1 cells. Anticancer Res. 19:487–491.
1999.PubMed/NCBI
|
|
65
|
Wang W, Wang H, Rayburn ER, Zhao Y, Hill
DL and Zhang R: 20(S)-25-methoxyl-dammarane-3beta, 12beta,
20-triol, a novel natural product for prostate cancer therapy:
activity in vitro and in vivo and mechanisms of action. Br J
Cancer. 98:792–802. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Park S, Lee HJ, Jeong SJ, et al:
Inhibition of JAK1/STAT3 signaling mediates compound K-induced
apoptosis in human multiple myeloma U266 cells. Food Chem Toxicol.
49:1367–1372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sathishkumar N, Sathiyamoorthy S, Ramya M,
Yang DU, Lee HN and Yang DC: Molecular docking studies of
anti-apoptotic BCL-2, BCL-XL, and MCL-1 proteins with ginsenosides
from Panax ginseng. J Enzyme Inhib Med Chem. 27:685–692.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Liu J, Shimizu K, Yu H, Zhang C, Jin F and
Kondo R: Stereospecificity of hydroxyl group at C-20 in
antiproliferative action of ginsenoside Rh2 on prostate cancer
cells. Fitoterapia. 81:902–905. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Dong H, Bai LP, Wong VK, et al: The in
vitro structure-related anti-cancer activity of ginsenosides and
their derivatives. Molecules. 16:10619–10630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Chen QJ, Zhang MZ and Wang LX: Gensenoside
Rg3 inhibits hypoxia-induced VEGF expression in human cancer cells.
Cell Physiol Biochem. 26:849–858. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Yue PY, Wong DY, Wu PK, et al: The
angiosuppressive effects of 20(R)- ginsenoside Rg3. Biochem
Pharmacol. 72:437–445. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Zhang Q, Kang X, Yang B, Wang J and Yang
F: Antiangiogenic effect of capecitabine combined with ginsenoside
Rg3 on breast cancer in mice. Cancer Biother Radiopharm.
23:647–653. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Xu TM, Xin Y, Cui MH, Jiang X and Gu LP:
Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide
on growth and angiogenesis of ovarian cancer. Chin Med J (Engl).
120:584–588. 2007.PubMed/NCBI
|
|
74
|
Zhang Q, Kang X and Zhao W: Antiangiogenic
effect of low-dose cyclophosphamide combined with ginsenoside Rg3
on Lewis lung carcinoma. Biochem Biophys Res Commun. 342:824–828.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Kim JW, Jung SY, Kwon YH, et al:
Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting
bioactivities of endothelial progenitor cells. Cancer Biol Ther.
13:504–515. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Sato K, Mochizuki M, Saiki I, Yoo YC,
Samukawa K and Azuma I: Inhibition of tumor angiogenesis and
metastasis by a saponin of Panax ginseng, ginsenoside-Rb2.
Biol Pharm Bull. 17:635–639. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Jeong A, Lee HJ, Jeong SJ, Lee EO, Bae H
and Kim SH: Compound K inhibits basic fibroblast growth
factor-induced angiogenesis via regulation of p38 mitogen activated
protein kinase and AKT in human umbilical vein endothelial cells.
Biol Pharm Bull. 33:945–950. 2010. View Article : Google Scholar
|
|
78
|
Pan XY, Guo H, Han J, et al: Ginsenoside
Rg3 attenuates cell migration via inhibition of aquaporin 1
expression in PC-3M prostate cancer cells. Eur J Pharmacol.
683:27–34. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Mochizuki M, Yoo YC, Matsuzawa K, et al:
Inhibitory effect of tumor metastasis in mice by saponins,
ginsenoside-Rb2, 20(R)- and 20(S)-ginsenoside-Rg3, of red ginseng.
Biol Pharm Bull. 18:1197–1202. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Xu TM, Cui MH, Xin Y, et al: Inhibitory
effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin Med J
(Engl). 121:1394–1397. 2008.PubMed/NCBI
|
|
81
|
Chen XP, Qian LL, Jiang H and Chen JH:
Ginsenoside Rg3 inhibits CXCR4 expression and related migrations in
a breast cancer cell line. Int J Clin Oncol. 16:519–523. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Iishi H, Tatsuta M, Baba M, et al:
Inhibition by ginsenoside Rg3 of bombesin-enhanced peritoneal
metastasis of intestinal adenocarcinomas induced by azoxymethane in
Wistar rats. Clin Exp Metastasis. 15:603–611. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Shinkai K, Akedo H, Mukai M, et al:
Inhibition of in vitro tumor cell invasion by ginsenoside Rg3. Jpn
J Cancer Res. 87:357–362. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Yoon JH, Choi YJ and Lee SG: Ginsenoside
Rh1 suppresses matrix metalloproteinase-1 expression through
inhibition of activator protein-1 and mitogen-activated protein
kinase signaling pathway in human hepatocellular carcinoma cells.
Eur J Pharmacol. 679:24–33. 2012. View Article : Google Scholar
|
|
85
|
Yoon JH, Choi YJ, Cha SW and Lee SG:
Anti-metastatic effects of ginsenoside Rd via inactivation of MAPK
signaling and induction of focal adhesion formation. Phytomedicine.
19:284–292. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Kim SY, Kim DH, Han SJ, Hyun JW and Kim
HS: Repression of matrix metalloproteinase gene expression by
ginsenoside Rh2 in human astroglioma cells. Biochem Pharmacol.
74:1642–1651. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ming Y, Chen Z, Chen L, et al: Ginsenoside
compound K attenuates metastatic growth of hepatocellular
carcinoma, which is associated with the translocation of nuclear
factor-kappaB p65 and reduction of matrix metalloproteinase-2/9.
Planta Med. 77:428–433. 2011. View Article : Google Scholar
|
|
88
|
Hasegawa H and Uchiyama M: Antimetastatic
efficacy of orally administered ginsenoside Rb1 in dependence on
intestinal bacterial hydrolyzing potential and significance of
treatment with an active bacterial metabolite. Planta Med.
64:696–700. 1998. View Article : Google Scholar
|
|
89
|
Choo MK, Sakurai H, Kim DH and Saiki I: A
ginseng saponin metabolite suppresses tumor necrosis
factor-α-promoted metastasis by suppressing nuclear factor-κB
signaling in murine colon cancer cells. Oncol Rep. 19:595–600.
2008.PubMed/NCBI
|
|
90
|
Kim SM, Lee SY, Yuk DY, et al: Inhibition
of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of
colon cancer cells to docetaxel. Arch Pharm Res. 32:755–765. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Kim SM, Lee SY, Cho JS, et al: Combination
of ginsenoside Rg3 with docetaxel enhances the susceptibility of
prostate cancer cells via inhibition of NF-kappaB. Eur J Pharmacol.
631:1–9. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Musende AG, Eberding A, Jia W, Ramsay E,
Bally MB and Guns ET: Rh2 or its aglycone aPPD in combination with
docetaxel for treatment of prostate cancer. Prostate. 70:1437–1447.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Yang LQ, Wang B, Gan H, et al: Enhanced
oral bioavailability and anti-tumour effect of paclitaxel by
20(s)-ginsenoside Rg3 in vivo. Biopharm Drug Dispos.
33:425–436. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Pokharel YR, Kim ND, Han HK, Oh WK and
Kang KW: Increased ubiquitination of multidrug resistance 1 by
ginsenoside Rd. Nutr Cancer. 62:252–259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lee CK, Park KK, Chung AS and Chung WY:
Ginsenoside Rg3 enhances the chemosensitivity of tumors to
cisplatin by reducing the basal level of nuclear factor erythroid
2-related factor 2-mediated heme oxygenase-1/NAD(P)H quinone
oxidoreductase-1 and prevents normal tissue damage by scavenging
cisplatin-induced intracellular reactive oxygen species. Food Chem
Toxicol. 50:2565–2574. 2012.
|
|
96
|
Kikuchi Y, Sasa H, Kita T, Hirata J, Tode
T and Nagata I: Inhibition of human ovarian cancer cell
proliferation in vitro by ginsenoside Rh2 and adjuvant effects to
cisplatin in vivo. Anticancer Drugs. 2:63–67. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Xie X, Eberding A, Madera C, et al: Rh2
synergistically enhances paclitaxel or mitoxantrone in prostate
cancer models. J Urol. 175:1926–1931. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Jia WW, Bu X, Philips D, et al: Rh2, a
compound extracted from ginseng, hypersensitizes
multidrug-resistant tumor cells to chemotherapy. Can J Physiol
Pharmacol. 82:431–437. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Chae S, Kang KA, Chang WY, et al: Effect
of compound K, a metabolite of ginseng saponin, combined with
gamma-ray radiation in human lung cancer cells in vitro and in
vivo. J Agric Food Chem. 57:5777–5782. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Park SA, Kim EH, Na HK and Surh YJ: KG-135
inhibits COX-2 expression by blocking the activation of JNK and
AP-1 in phorbol ester-stimulated human breast epithelial cells. Ann
NY Acad Sci. 1095:545–553. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Yoo JH, Kwon HC, Kim YJ, Park JH and Yang
HO: KG-135, enriched with selected ginsenosides, inhibits the
proliferation of human prostate cancer cells in culture and
inhibits xenograft growth in athymic mice. Cancer Lett. 289:99–110.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Lee WH, Choi JS, Kim HY, et al:
Potentiation of etoposide-induced apoptosis in HeLa cells by
co-treatment with KG-135, a quality-controlled standardized
ginsenoside formulation. Cancer Lett. 294:74–81. 2010. View Article : Google Scholar
|
|
103
|
Tatsuka M, Maeda M and Ota T:
Anticarcinogenic effect and enhancement of metastatic potential of
BALB/c 3T3 cells by ginsenoside Rh(2). Jpn J Cancer Res.
92:1184–1189. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Jeong HG, Pokharel YR, Han EH and Kang KW:
Induction of cyclooxygenase-2 by ginsenoside Rd via activation of
CCAAT-enhancer binding proteins and cyclic AMP response binding
protein. Biochem Biophys Res Commun. 359:51–56. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Kim JH, Park CY and Lee SJ: Effects of sun
ginseng on subjective quality of life in cancer patients: a
double-blind, placebo-controlled pilot trial. J Clin Pharm Ther.
31:331–334. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Lu P, Su W, Miao ZH, Niu HR, Liu J and Hua
QL: Effect and mechanism of ginsenoside Rg3 on postoperative life
span of patients with non-small cell lung cancer. Chin J Integr
Med. 14:33–36. 2008. View Article : Google Scholar : PubMed/NCBI
|
